MA42818A - Modulateurs de récepteurs de type toll pour le traitement du vih - Google Patents
Modulateurs de récepteurs de type toll pour le traitement du vihInfo
- Publication number
- MA42818A MA42818A MA042818A MA42818A MA42818A MA 42818 A MA42818 A MA 42818A MA 042818 A MA042818 A MA 042818A MA 42818 A MA42818 A MA 42818A MA 42818 A MA42818 A MA 42818A
- Authority
- MA
- Morocco
- Prior art keywords
- toll
- receptor modulators
- type receptor
- hiv treatment
- hiv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562218858P | 2015-09-15 | 2015-09-15 | |
| US201662382550P | 2016-09-01 | 2016-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42818A true MA42818A (fr) | 2018-07-25 |
Family
ID=56997570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042818A MA42818A (fr) | 2015-09-15 | 2016-09-13 | Modulateurs de récepteurs de type toll pour le traitement du vih |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20180263985A1 (fr) |
| EP (1) | EP3349757A1 (fr) |
| JP (1) | JP2018527366A (fr) |
| AU (1) | AU2016322763A1 (fr) |
| CA (1) | CA2997955A1 (fr) |
| HK (1) | HK1257270A1 (fr) |
| MA (1) | MA42818A (fr) |
| WO (1) | WO2017048727A1 (fr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008009078A2 (fr) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Dérivés de la quinazoline tri-substitués en 4,6-dl et en 2,4,6 utilisables pour traiter les infections virales |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| US9670205B2 (en) | 2015-03-04 | 2017-06-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018045150A1 (fr) * | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Dérivés de 4,6-diamino-pyrido [3,2-d] pyrimidine en tant que modulateurs du récepteur de type toll |
| AU2017318601B2 (en) * | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| FR3066761B1 (fr) * | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
| CN108069963B (zh) * | 2017-11-17 | 2020-01-14 | 清华大学 | 吡啶并嘧啶衍生物或其盐及其制法、药物组合物和用途 |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| CN115710266B (zh) * | 2018-07-03 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| MX2021002764A (es) | 2018-09-12 | 2021-05-12 | Silverback Therapeutics Inc | Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores. |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| TWI751516B (zh) * | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) * | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| KR20240137107A (ko) * | 2019-07-16 | 2024-09-19 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| JP2022545872A (ja) * | 2019-08-19 | 2022-11-01 | シャンハイ ジムン バイオファーマ，インコーポレーテッド | ２―アミノピリミジン化合物ならびにその医薬組成物および用途 |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| CA3151322A1 (fr) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Polytherapie comprenant des conjugues immunostimulants |
| EP3821890A1 (fr) * | 2019-11-18 | 2021-05-19 | Strumberg, Dirk | Compositions pharmaceutiques comprenant un inhibiteur de l'histone désacétylase (hdaci) et un agoniste de récepteur de type toll 7 et/ou 8 (tlr7 et/ou tlr8) et leur utilisation dans le traitement du cancer |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| KR20220123437A (ko) * | 2020-01-02 | 2022-09-06 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 피리도피리미딘 유도체의 결정형 및 이의 제조 방법 |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| WO2021188959A1 (fr) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Promédicaments de nucléosides de 4'-c-substitué-2-halo-2'-désoxyadénosine et leurs procédés de fabrication et d'utilisation |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| PL4244396T3 (pl) | 2020-11-11 | 2025-12-22 | Gilead Sciences, Inc. | Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120 |
| US12053517B2 (en) | 2021-01-14 | 2024-08-06 | Gilead Sciences, Inc. | HIV vaccines and methods of using |
| WO2022241134A1 (fr) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Combinaison d'un composé de modulation de tlr8 et agent thérapeutique anti-arnsi de vhb |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CR20240223A (es) | 2021-12-03 | 2024-07-08 | Gilead Sciences Inc | Compuestos terapéuticos para la infección por el virus del vih |
| US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| US12404262B2 (en) | 2021-12-03 | 2025-09-02 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TWI867601B (zh) | 2022-07-01 | 2024-12-21 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| AU2023330037A1 (en) | 2022-08-26 | 2025-03-06 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| US20240390349A1 (en) | 2023-04-19 | 2024-11-28 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| CN121219281A (zh) | 2023-05-31 | 2025-12-26 | 吉利德科学公司 | 用于治疗hiv的化合物的固体形式 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| WO2025029247A1 (fr) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Régime hebdomadaire de lénacapavir pour le traitement et la prévention du vih |
| WO2025042394A1 (fr) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Schéma posologique d'un inhibiteur de capside du vih |
| US20250122219A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184452A1 (fr) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Formes solides d'inhibiteurs de l'intégrase du vih |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025240242A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec ribavirine |
| WO2025240243A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies comprenant du bulévirtide et un acide nucléique inhibiteur ciblant le virus de l'hépatite b |
| WO2025240244A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies comprenant du bulévirtide et du lonafarnib destinées à être utilisées dans le traitement d'une infection par le virus de l'hépatite d |
| WO2025240246A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec de la ribavirine |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2026076265A1 (fr) | 2024-10-03 | 2026-04-09 | Gilead Sciences, Inc. | Thérapie de combinaison comprenant des composés de carbamoylpyridone tricycliques pontés et des inhibiteurs de la p-glycoprotéine |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4724232A (en) | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| CS263952B1 (en) | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
| AU570853B2 (en) | 1985-08-26 | 1988-03-24 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases |
| US6492352B1 (en) | 1985-10-31 | 2002-12-10 | Astra Lakemedel Aktiebolag | Method for the control and treatment of acquired immunodeficiency syndrome (AIDS) |
| US4978655A (en) | 1986-12-17 | 1990-12-18 | Yale University | Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses |
| US5028595A (en) | 1987-09-18 | 1991-07-02 | Hoffmann-La Roche Inc. | Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus |
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| US5366972A (en) | 1989-04-20 | 1994-11-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection |
| US5539122A (en) | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| GB8927913D0 (en) | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| US5563142A (en) | 1989-12-28 | 1996-10-08 | The Upjohn Company | Diaromatic substituted compounds as anti-HIV-1 agents |
| US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5665720A (en) | 1992-08-07 | 1997-09-09 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US5646180A (en) | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
| US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| EP2497831B1 (fr) | 2004-05-25 | 2014-07-16 | Oregon Health and Science University | Vaccin contre la Tuberculosis utilisant des vecteurs de vaccin à base de HCMV |
| DK1877090T3 (da) | 2005-05-06 | 2014-04-14 | Providence Health System | Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf |
| AU2006261607A1 (en) * | 2005-06-24 | 2006-12-28 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis C. |
| TW201402124A (zh) * | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| WO2008077649A1 (fr) * | 2006-12-26 | 2008-07-03 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines utiles pour traiter des infections virales |
| TW200840584A (en) * | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
| EA019259B1 (ru) | 2007-11-16 | 2014-02-28 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| WO2010014913A1 (fr) | 2008-08-01 | 2010-02-04 | Ventirx Pharmaceuticals, Inc. | Formulations d'agoniste des récepteurs de type toll et leur utilisation |
| SI3260136T1 (sl) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| CN105669553A (zh) | 2009-08-18 | 2016-06-15 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
| RU2016108987A (ru) | 2009-08-18 | 2018-11-26 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора |
| US20110305670A1 (en) | 2010-06-10 | 2011-12-15 | President And Fellows Of Harvard College | Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection |
| MX2012015097A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Derivados de acido naft-2-ilacetico para tratar sida. |
| EP2588455B1 (fr) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | Dérivés de l'acide 2-quinolinyl-acétique en tant que composés antiviraux hiv |
| PT3556396T (pt) | 2010-08-31 | 2022-07-04 | Scripps Research Inst | Anticorpos neutralizantes do vírus da imunodeficiência humana (vih) |
| EP3195868A3 (fr) | 2010-10-01 | 2017-08-02 | VentiRx Pharmaceuticals, Inc. | Utilisation thérapeutique d'un agoniste de tlr, et polythérapie |
| CN103237549A (zh) | 2010-10-01 | 2013-08-07 | 帆德制药股份有限公司 | 过敏性疾病的治疗方法 |
| JP2013545749A (ja) * | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| EP3208263A1 (fr) | 2011-01-12 | 2017-08-23 | VentiRx Pharmaceuticals, Inc. | Benzoazépines substituées en tant que modulateurs de récepteurs de type toll |
| PT3590928T (pt) | 2011-04-08 | 2021-08-19 | Janssen Sciences Ireland Unlimited Co | Derivados de pirimidina para o tratamento de infeções virais |
| CA2871089A1 (fr) | 2011-04-20 | 2012-10-26 | Smith Holdings, Llc | Procedes et compositions de modulation de l'expression des genes a l'aide de composants qui sont auto-assembles dans des cellules et qui produisent une activite d'arni |
| UA111841C2 (uk) | 2011-04-21 | 2016-06-24 | Гіліад Сайєнсіз, Інк. | Сполуки бензотіазолу та їх фармацевтичне застосування |
| AU2012258220B2 (en) | 2011-05-18 | 2017-01-19 | Janssen Sciences Ireland Uc | Quinazoline derivatives for the treatment of viral infections and further diseases |
| HK1198443A1 (en) * | 2011-07-19 | 2015-04-24 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| SG11201404743TA (en) | 2012-02-08 | 2014-09-26 | Janssen R & D Ireland | Piperidino-pyrimidine derivatives for the treatment of viral infections |
| UY34750A (es) | 2012-04-20 | 2013-11-29 | Gilead Sciences Inc | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. |
| WO2013163427A1 (fr) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Anticorps pour traiter les infections par le vih-1 |
| MX369417B (es) | 2012-08-10 | 2019-11-07 | Janssen Sciences Ireland Uc | Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades. |
| DK2906563T3 (en) | 2012-10-10 | 2018-06-06 | Janssen Sciences Ireland Uc | PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES |
| EA035431B1 (ru) | 2012-11-16 | 2020-06-15 | Янссен Сайенсиз Айрлэнд Юси | Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций |
| SG11201506639XA (en) | 2013-02-21 | 2015-09-29 | Janssen Sciences Ireland Uc | 2-aminopyrimidine derivatives for the treatment of viral infections |
| NO2865735T3 (fr) | 2013-07-12 | 2018-07-21 | ||
| ES2859102T3 (es) | 2013-07-12 | 2021-10-01 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH |
| US9670205B2 (en) * | 2015-03-04 | 2017-06-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
-
2016
- 2016-09-13 CA CA2997955A patent/CA2997955A1/fr not_active Abandoned
- 2016-09-13 US US15/759,177 patent/US20180263985A1/en not_active Abandoned
- 2016-09-13 US US15/264,401 patent/US20170071944A1/en not_active Abandoned
- 2016-09-13 AU AU2016322763A patent/AU2016322763A1/en not_active Abandoned
- 2016-09-13 WO PCT/US2016/051545 patent/WO2017048727A1/fr not_active Ceased
- 2016-09-13 HK HK18116414.4A patent/HK1257270A1/zh unknown
- 2016-09-13 MA MA042818A patent/MA42818A/fr unknown
- 2016-09-13 EP EP16770854.4A patent/EP3349757A1/fr not_active Withdrawn
- 2016-09-13 JP JP2018513529A patent/JP2018527366A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3349757A1 (fr) | 2018-07-25 |
| JP2018527366A (ja) | 2018-09-20 |
| CA2997955A1 (fr) | 2017-03-23 |
| WO2017048727A1 (fr) | 2017-03-23 |
| AU2016322763A1 (en) | 2018-04-19 |
| US20170071944A1 (en) | 2017-03-16 |
| HK1257270A1 (zh) | 2019-10-18 |
| US20180263985A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42818A (fr) | Modulateurs de récepteurs de type toll pour le traitement du vih | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
| EP3364904A4 (fr) | Balayage variable pour dispositifs d'entrée | |
| EP3488338A4 (fr) | Technologies pour le traitement adaptatif de tampons multiples | |
| EP3277465A4 (fr) | Mécanisme de levage pour cloueuse de charpente | |
| MA48448A (fr) | Dérivés de quinazoline utilisés pour traiter le vih | |
| EP3351189A4 (fr) | Instrument de traitement pour endoscope | |
| EP3482506A4 (fr) | Relaxation de traitement pour csi-rs apériodiques | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| EP3630078A4 (fr) | Agents pour chimio-embolisation | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| EP3374502A4 (fr) | Procédés pour le traitement de dystrophies cornéennes | |
| EP3621592A4 (fr) | Polythérapies pour le traitement du cancer | |
| DK3359160T3 (da) | Farnesoid x receptor modulatorer | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| FR3036518B1 (fr) | Inversion pour contrainte tectonique | |
| EP3335041A4 (fr) | Biomarqueurs pour le traitement de la pelade | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3690324A4 (fr) | Système de traitement de fumée pour sauteuse et sauteuse | |
| EP3383407A4 (fr) | Conjugués de cytarabine pour le traitement du cancer | |
| FR3042807B1 (fr) | Autolestage pour banche de coffrage | |
| EP3334432A4 (fr) | Cerdulatinib pour le traitement du myélome | |
| EP3395291A4 (fr) | Dispositif de suspension pour instrument dentaire | |
| EP3349793A4 (fr) | Anti-s100a8 pour le traitement de la leucémie |